JP2004537500A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004537500A5 JP2004537500A5 JP2002555834A JP2002555834A JP2004537500A5 JP 2004537500 A5 JP2004537500 A5 JP 2004537500A5 JP 2002555834 A JP2002555834 A JP 2002555834A JP 2002555834 A JP2002555834 A JP 2002555834A JP 2004537500 A5 JP2004537500 A5 JP 2004537500A5
- Authority
- JP
- Japan
- Prior art keywords
- inhibitor
- patient
- nature
- body weight
- per
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003112 inhibitor Substances 0.000 description 5
- 230000037396 body weight Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US69360000A | 2000-10-20 | 2000-10-20 | |
| US31818501P | 2001-09-07 | 2001-09-07 | |
| PCT/US2001/051339 WO2002055100A2 (en) | 2000-10-20 | 2001-10-22 | Method and composition for inhibition of tumor growth and enhancing an immune response |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008262301A Division JP2009046512A (ja) | 2000-10-20 | 2008-10-08 | 腫瘍の増殖の阻害および免疫応答の増強のための方法および組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004537500A JP2004537500A (ja) | 2004-12-16 |
| JP2004537500A5 true JP2004537500A5 (OSRAM) | 2005-04-21 |
Family
ID=26981351
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002555834A Pending JP2004537500A (ja) | 2000-10-20 | 2001-10-22 | 腫瘍の増殖の阻害および免疫応答の増強のための方法および組成物 |
| JP2008262301A Pending JP2009046512A (ja) | 2000-10-20 | 2008-10-08 | 腫瘍の増殖の阻害および免疫応答の増強のための方法および組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008262301A Pending JP2009046512A (ja) | 2000-10-20 | 2008-10-08 | 腫瘍の増殖の阻害および免疫応答の増強のための方法および組成物 |
Country Status (8)
| Country | Link |
|---|---|
| EP (2) | EP2027867A1 (OSRAM) |
| JP (2) | JP2004537500A (OSRAM) |
| AT (1) | ATE405282T1 (OSRAM) |
| AU (1) | AU2002243443A1 (OSRAM) |
| DE (1) | DE60135481D1 (OSRAM) |
| DK (1) | DK1333850T3 (OSRAM) |
| ES (1) | ES2311558T3 (OSRAM) |
| WO (1) | WO2002055100A2 (OSRAM) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050069546A1 (en) * | 2003-09-30 | 2005-03-31 | Yaron Ilan | Educated NKT cells and their uses in the treatment of immune-related disorders |
| ES2775204T3 (es) | 2003-12-23 | 2020-07-24 | Genentech Inc | Nuevos anticuerpos anti IL13 y usos de los mismos |
| CA2557724A1 (en) * | 2004-02-27 | 2005-10-06 | Centocor, Inc. | Methods and compositions for treating il-13 related pathologies |
| AR049390A1 (es) | 2004-06-09 | 2006-07-26 | Wyeth Corp | Anticuerpos contra la interleuquina-13 humana y usos de los mismos |
| US7501121B2 (en) | 2004-06-17 | 2009-03-10 | Wyeth | IL-13 binding agents |
| CA2587903A1 (en) | 2004-11-17 | 2006-05-26 | Amgen Fremont Inc. | Fully human monoclonal antibodies to il-13 |
| CA2593714C (en) * | 2005-02-04 | 2013-09-10 | Survac Aps | Survivin peptide vaccine |
| JP2010502224A (ja) | 2006-09-08 | 2010-01-28 | アボット・ラボラトリーズ | インターロイキン１３結合タンパク質 |
| WO2011003138A1 (en) * | 2009-07-06 | 2011-01-13 | The Australian National University | Immunomodulating compositions comprising interleukin 13 inhibitors and uses therefor |
| WO2012083132A2 (en) | 2010-12-16 | 2012-06-21 | Genentech, Inc. | Diagnosis and treatments relating to th2 inhibition |
| US8466159B2 (en) | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
| US8492386B2 (en) | 2011-10-21 | 2013-07-23 | Abbvie Inc. | Methods for treating HCV |
| EP2583680A3 (en) | 2011-10-21 | 2013-06-12 | Abbvie Inc. | Mono (PSI-7977) or combination treatment of DAAs for use in treating HCV |
| AU2013201406B2 (en) | 2011-10-21 | 2014-10-02 | Abbvie Ireland Unlimited Company | Methods for treating HCV |
| NZ756750A (en) | 2013-09-13 | 2022-05-27 | Genentech Inc | Methods and compositions comprising purified recombinant polypeptides |
| ES2915378T3 (es) | 2013-09-13 | 2022-06-22 | Hoffmann La Roche | Procedimientos para detectar y cuantificar una proteína de célula huésped en líneas celulares |
| US20170165364A1 (en) * | 2014-02-21 | 2017-06-15 | Idac Theranostics, Inc. | Therapeutic agent for solid cancer |
| WO2017189978A1 (en) | 2016-04-28 | 2017-11-02 | Emory University | Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto |
| WO2025015130A1 (en) * | 2023-07-12 | 2025-01-16 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Compositions and methods for the inhibition of natural killer cells |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6294322B1 (en) | 1988-01-26 | 2001-09-25 | The United States Of America As Represented By The Department Of Health And Human Services | Multideterminant peptides that elicit helper T-lymphocyte cytotoxic T-lymphocyte and neutralizing antibody responses against HIV-1 |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| AU5010793A (en) * | 1992-08-21 | 1994-03-15 | Schering Corporation | Human interleukin-13 |
| US20010053371A1 (en) * | 1999-01-07 | 2001-12-20 | Waldemar Debinski | Method for diagnosing, imaging, and treating tumors using restrictive receptor for interleukin 13 |
| JPH09150569A (ja) | 1995-11-29 | 1997-06-10 | Riso Kagaku Corp | 色画像形成用シート |
| GB9625899D0 (en) * | 1996-12-13 | 1997-01-29 | Glaxo Group Ltd | Substances and their uses |
| US6013258A (en) | 1997-10-09 | 2000-01-11 | Zycos Inc. | Immunogenic peptides from the HPV E7 protein |
| DE69933696T2 (de) * | 1998-12-14 | 2007-08-23 | Genetics Institute, LLC, Cambridge | Cytokinrezeptor-kette |
| DE60017115T2 (de) * | 1999-02-10 | 2005-12-08 | Mitsubishi Pharma Corp. | Amid-derivate und deren medizinische verwendung |
| AU2001253282A1 (en) * | 2000-04-07 | 2001-10-23 | Heska Corporation | Compositions and methods related to canine igg and canine il-13 receptors |
-
2001
- 2001-10-22 EP EP08105062A patent/EP2027867A1/en not_active Withdrawn
- 2001-10-22 DE DE60135481T patent/DE60135481D1/de not_active Expired - Lifetime
- 2001-10-22 EP EP01989341A patent/EP1333850B1/en not_active Revoked
- 2001-10-22 ES ES01989341T patent/ES2311558T3/es not_active Expired - Lifetime
- 2001-10-22 WO PCT/US2001/051339 patent/WO2002055100A2/en not_active Ceased
- 2001-10-22 AU AU2002243443A patent/AU2002243443A1/en not_active Abandoned
- 2001-10-22 JP JP2002555834A patent/JP2004537500A/ja active Pending
- 2001-10-22 AT AT01989341T patent/ATE405282T1/de not_active IP Right Cessation
- 2001-10-22 DK DK01989341T patent/DK1333850T3/da active
-
2008
- 2008-10-08 JP JP2008262301A patent/JP2009046512A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004537500A5 (OSRAM) | ||
| NZ592039A (en) | Combination therapy for the treatment of ocular neovascular disorders | |
| NZ527113A (en) | Rapid-onset medicament for the treatment of sexual dysfunction | |
| WO2000064441A3 (en) | Compound for use as a medicament for treatment of disorders involving bronchocontraction | |
| WO2002041883A3 (en) | As-needed administration of tricyclic and other non-sri antidepressant drugs to treat premature ejaculation | |
| JP2002522485A5 (OSRAM) | ||
| TW200501983A (en) | Uses of anti-insulin-like growth factor I receptor antibodies | |
| JP2002528502A5 (OSRAM) | ||
| WO2004045593A3 (en) | Combination cancer therapy with a gst-activated anticancer compound and another anticancer therapy | |
| WO2004039325A3 (en) | Treatment of pain with jnk inhibitors | |
| JP2001510795A5 (OSRAM) | ||
| JP2002524415A5 (OSRAM) | ||
| RU2004135563A (ru) | Лекарственное средство для лечения повышенной активности мочевого пузыря | |
| WO2006029036A3 (en) | Combination therapy with glatiramer acetate and n-acetylcysteine for the treatment of multiple sclerosis | |
| WO2001068125A3 (en) | Methods and compositions for the treatment and prevention of erectile dysfunction | |
| WO2005011579A3 (en) | Treatment of dependence withdrawal | |
| WO2004093881A3 (en) | Use of dipyridamole or mopidamole for treatment and prevention of thrombo-embolic diseases and disorders caused by excessive formation of thrombin and/or by elevated expression of thrombin receptors | |
| WO2002034267A8 (de) | Kombination eines transdermalen therapeutischen systems und einer oralen und/oder parenteralen zubereitung enthaltend dopaminagonisten zur behandlung dopaminerger erkrankungen | |
| JP2003504332A5 (OSRAM) | ||
| CA2433833A1 (en) | Use of flumazenil in developing a drug for the treatment of alcohol dependence | |
| JP2002523437A5 (OSRAM) | ||
| CA2313270A1 (en) | Use of deferiprone in treating and preventing iron-induced cardiac disease | |
| WO2004050025A3 (en) | Combination of ibuprofen and oxycodone for acute pain relief | |
| WO2005094899A8 (en) | Clusterin antisense therapy for treatment of cancer | |
| JP2003528919A5 (OSRAM) |